Movi-Cox Contraindications

Known hypersensitivity to meloxicam or to any of the excipient of Movi-Cox. There is a potential for cross-sensitivity to acetylsalicylic acid and other NSAIDs.
Patients who have developed signs of asthma, nasal polyps, angioedema or urticaria following the administration of acetosal or other NSAIDs.
Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Active or recent GI ulceration/perforation; active inflammatory bowel disease (Crohn's disease or ulcerative colitis); severe hepatic insufficiency; non-dialysed severe renal insufficiency; overt GI bleeding, recent cerebrovascular bleeding or established systemic bleeding disorders; severe uncontrolled heart failure.
In case of rare hereditary conditions that may be incompatible with an excipient of the product (see Precautions), and pregnancy and lactation, children and adolescents <15 years, the use of Movi-Cox is contraindicated.
Effects on the Ability to Drive or Operate Machinery: No studies on the effect on the ability to drive and use machines have been performed. However, patients should be advised that they may experience undesirable effects like visual disturbance including blurred vision, dizziness, somnolence, vertigo and other central nervous system disturbances.
Therefore, caution should be recommended when driving a car or operating a machinery.
If patients experience any of these events, they should avoid potentially hazardous tasks eg, driving or operating machinery.
Use in pregnancy & lactation: Movi-Cox is contraindicated during pregnancy. Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or the embryofoetal development. Data from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastrochisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from <1% up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In preclinical studies, administration of a prostaglandin synthesis inhibitor has been shown to result an increase in pre- and post-implantation loss and embryofoetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in preclinical studies given a prostaglandin synthesis inhibitor during the organogenetic period.
During the 3rd trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to: Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the neonate, at the end of pregnancy, to: Possible prolongation of bleeding time, an antiaggregating effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labour.
While no specific experience exists for Movi-Cox, NSAIDs are known to pass into mother's milk. Administration therefore is contraindicated in women who are breastfeeding.
The use of meloxicam, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. Meloxicam may delay ovulation. Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, withdrawal of meloxicam should be considered.